{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:21:19Z","timestamp":1792092079459,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7244475"],"award-info":[{"award-number":["7244475"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022815","name":"Beijing Tongren Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004147","name":"Tsinghua University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016126","name":"Beijing Hospital Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109731","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:23:59Z","timestamp":1772781839000},"page":"109731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design, synthesis, and pharmacological evaluation of novel PROTAC degraders targeting 11\u03b2-HSD1 for metabolic disease intervention"],"prefix":"10.1016","volume":"174","author":[{"given":"Liguo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.bioorg.2026.109731_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39534","article-title":"Blockade of 11beta-hydroxysteroid dehydrogenase type 1 ameliorates metabolic dysfunction-associated steatotic liver disease and fibrosis","volume":"10","author":"Ma","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109731_bb0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action","volume":"93","author":"Chapman","year":"2013","journal-title":"Physiol. Rev."},{"issue":"17","key":"10.1016\/j.bioorg.2026.109731_bb0015","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1073\/pnas.0306996101","article-title":"11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics","volume":"101","author":"Sandeep","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109731_bb0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1677\/joe.1.06019","article-title":"11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action","volume":"186","author":"Draper","year":"2005","journal-title":"J. Endocrinol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109731_bb0025","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnaa002","article-title":"Dynamics of ACTH and cortisol secretion and implications for disease","volume":"41","author":"Lightman","year":"2020","journal-title":"Endocr. Rev."},{"issue":"24","key":"10.1016\/j.bioorg.2026.109731_bb0030","doi-asserted-by":"crossref","first-page":"E2482","DOI":"10.1073\/pnas.1323681111","article-title":"11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess","volume":"111","author":"Morgan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109731_bb0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjms.2017.03.023","article-title":"11beta-Hydroxysteroid dehydrogenase type 1 in obese subjects with type 2 diabetes mellitus","volume":"354","author":"Li","year":"2017","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109731_bb0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI17845","article-title":"Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice","volume":"112","author":"Masuzaki","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2026.109731_bb0045","doi-asserted-by":"crossref","DOI":"10.1186\/2050-6511-15-43","article-title":"A novel 11\u03b2-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6\/J mice with a potential to provide cardio protective benefits","volume":"15","author":"Anil","year":"2014","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"26","key":"10.1016\/j.bioorg.2026.109731_bb0050","doi-asserted-by":"crossref","first-page":"14924","DOI":"10.1073\/pnas.94.26.14924","article-title":"11\u03b2-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity orstress","volume":"94","author":"Kotelevtsev","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109731_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112921","article-title":"The role of glucocorticoids in inflammatory diseases","volume":"10","author":"Reichardt","year":"2021","journal-title":"Cells"},{"issue":"20","key":"10.1016\/j.bioorg.2026.109731_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11206190","article-title":"11beta-Hydroxysteroid dehydrogenase type 1 as a potential treatment target in cardiovascular diseases","volume":"11","author":"Kupczyk","year":"2022","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109731_bb0065","article-title":"BVT.2733, a selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109731_bb0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jash.2011.01.009","article-title":"Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension","volume":"5","author":"Shah","year":"2011","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.bioorg.2026.109731_bb0075","doi-asserted-by":"crossref","unstructured":"J. Rosenstock, S. Banarer, V.A. Fonseca, S.E. Inzucchi, W. Sun, W. Yao, G. Hollis, R. Flores, R. Levy, W.V. Williams, J.R. Seckl, R. Huber, I.P. Investigators, The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy, Diabetes Care 33(7) (2010) 1516\u201322. doi:https:\/\/doi.org\/10.2337\/dc09-2315.","DOI":"10.2337\/dc09-2315"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109731_bb0080","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1021\/acs.jmedchem.7b00211","article-title":"Discovery of clinical candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3\u2032-hydroxyazetidin-1-yl)ethanone [BMS-816336], an orally active novel selective 11beta-Hydroxysteroid dehydrogenase type 1 inhibitor","volume":"60","author":"Ye","year":"2017","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2026.109731_bb0085","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1111\/bph.13251","article-title":"Continuous inhibition of 11beta-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice","volume":"172","author":"Morentin Gutierrez","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109731_bb0090","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.bbamcr.2008.03.001","article-title":"Direct protein-protein interaction of 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the endoplasmic reticulum lumen","volume":"1783","author":"Atanasov","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"17","key":"10.1016\/j.bioorg.2026.109731_bb0095","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1016\/j.bmcl.2017.07.043","article-title":"Interplay between H6PDH and 11beta-HSD1 implicated in the pathogenesis of type 2 diabetes mellitus","volume":"27","author":"Yao","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.bioorg.2026.109731_bb0100","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109731_bb0105","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1161\/CIRCRESAHA.115.306825","article-title":"Epidemiology of obesity and diabetes and their cardiovascular complications","volume":"118","author":"Bhupathiraju","year":"2016","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109731_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17020238","article-title":"Advances in Oral biomacromolecule therapies for metabolic diseases","volume":"17","author":"Jiao","year":"2025","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.bioorg.2026.109731_bb0115","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.apsb.2020.11.001","article-title":"Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo","volume":"11","author":"Luo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109731_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.109577","article-title":"Developing selective PI3K degraders to modulate both kinase and non-kinase functions","volume":"35","author":"Yang","year":"2024","journal-title":"Chin. Chem. Lett."},{"issue":"14","key":"10.1016\/j.bioorg.2026.109731_bb0125","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1002\/anie.201913904","article-title":"Development of a PDEdelta-targeting PROTACs that impair lipid metabolism","volume":"59","author":"Winzker","year":"2020","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.bioorg.2026.109731_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106627","article-title":"Advancing targeted protein degradation for metabolic diseases therapy","volume":"188","author":"Zhou","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109731_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138292","article-title":"PROTAC-mediated FTO protein degradation effectively alleviates diet-induced obesity and hepatic steatosis","volume":"285","author":"Xiao","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109731_bb0140","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1039\/D5MD00252D","article-title":"Rational design and discovery of potent PROTAC degraders of ASK1: a targeted therapy in MASH","volume":"16","author":"Sarkar","year":"2025","journal-title":"RSC Med. Chem."},{"issue":"22","key":"10.1016\/j.bioorg.2026.109731_bb0145","doi-asserted-by":"crossref","first-page":"10136","DOI":"10.1021\/jm301252n","article-title":"Novel acidic 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329)","volume":"55","author":"Scott","year":"2012","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109731_bb0150","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/ci700257y","article-title":"Computation of octanol-water partition coefficients by guiding an additive model with knowledge","volume":"47","author":"Cheng","year":"2007","journal-title":"J. Chem. Inf. Model."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109731_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0311527","article-title":"Integration of pharmacophore-based virtual screening, molecular docking, ADMET analysis, and MD simulation for targeting EGFR: a comprehensive drug discovery study using commercial databases","volume":"19","author":"Alanzi","year":"2024","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109731_bb0160","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109731_bb0165","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41589-020-00652-y","article-title":"PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase","volume":"16","author":"Adhikari","year":"2020","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109731_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103985","article-title":"Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases","volume":"25","author":"Luo","year":"2022","journal-title":"iScience"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109731_bb0175","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.chembiol.2022.09.006","article-title":"Localization matters in targeted protein degradation","volume":"29","author":"Shah","year":"2022","journal-title":"Cell Chem. Biol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109731_bb0180","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s13238-018-0602-z","article-title":"Developing potent PROTACs tools for selective degradation of HDAC6 protein","volume":"10","author":"An","year":"2019","journal-title":"Protein Cell"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109731_bb0185","doi-asserted-by":"crossref","DOI":"10.1063\/5.0216272","article-title":"A comprehensive electron wavefunction analysis toolbox for chemists, Multiwfn","volume":"161","author":"Lu","year":"2024","journal-title":"J. Chem. Phys."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109731_bb0190","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"Multiwfn: a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2011","journal-title":"J. Comput. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109731_bb0195","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS","volume":"17","author":"Valdes-Tresanco","year":"2021","journal-title":"J. Chem. Theory Comput."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:49:09Z","timestamp":1774860549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826002671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"alternative-id":["S0045206826002671"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109731","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and pharmacological evaluation of novel PROTAC degraders targeting 11\u03b2-HSD1 for metabolic disease intervention","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109731"}}